A phase IV study of the safety of palivizumab (MEDI-493, Synagis) for prophylaxis of respiratory syncytial virus in children with congenital heart disease, protocol MI-CP48
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2005
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 30 Nov 2005 New trial record.